Kairos Pharma (NYSE American: KAPA) announced that President and Chief Scientific Officer Neil Bhowmick will present and moderate a discussion at the 24th Annual Discovery on Target Drug Discovery Conference, being held Sept. 28-Oct. 1 in Boston. Bhowmick will moderate a Sept. 30 breakout session titled “Winning the Race against Cancer Therapy Resistance,” focused on Kairos strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates.
Bhowmick will also deliver an oral plenary presentation Sept. 30 at 2:35 p.m. Eastern on KROS-101, Kairos drug candidate targeting solid tumors. The presentation will focus on KROS-101 targeting of GITR (“Glucocorticoid-Induced TNF Receptor”) to increase T-cell function and expand effector T-cells with anti-tumor activity.
To view the full press release, visit https://nnw.fm/DoHxL
NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://nnw.fm/KAPA
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer